Document:

Offer Letter

 Exhibit 10.1 
  
 April 30, 2004 
  
 Mr. David G. Ludvigson 
 19431 San Marcos Road 
 Saratoga, CA 95070 
  
 Dear David: 
  
 On behalf on Nanogen Inc.
(“Nanogen”), I am pleased to revise your employment arrangement and offer you the position of President and Chief Operating Officer with Nanogen Inc. on the terms outlined in this letter effective as of June 1, 2004. 
  
 You will be located in our San Diego office, and as President and Chief Operating Officer,
will be responsible for all business activities for Nanogen. You will continue to devote your full-time efforts to these responsibilities and you will be compensated at an annual base rate of $300,000 per annum payable in equal, semi-monthly
increments. You will continue to report to me in my role as CEO of Nanogen. 
  
 As
President and Chief Operating Officer, you will continue to be a participant in Nanogen’s Executive Incentive Compensation Plan. As part of this plan, you will be eligible for an annual bonus of up to 55% of your annual salary composed as
follows: you may earn up to 30% of your annual salary, based on annual milestones as mutually agreed upon between you and me, subject to Board of Directors’ approval; you may also earn up to 25% of your annual salary, based solely on the
discretion of the Board of Directors. 
  
 As a regular employee of Nanogen, you
will continue to participate in Company-sponsored benefits. At present, these include full medical, dental, life and long-term disability insurance coverage for yourself with the option to include your family with a minimal contribution. In
addition, you will continue to be eligible to participate in our 401(k) plan and our 125 Flexible Benefits Program. You will be entitled to four weeks annual vacation. 
  
 Upon approval of the Nanogen Compensation Committee, you will be entitled to purchase 300,000 shares of Nanogen common stock at fair market
value, as determined by the closing price of Nanogen common stock on such date of approval. The purchase will be made through either the signing of Nanogen’s current form of Stock Purchase Agreement or Stock Options Agreement as provided in
Nanogen’s Stock Options Plan. These shares shall vest ratably on a monthly basis over the four-year period starting on the date of approval by the Compensation Committee. Vesting of the shares will be accelerated in the event of a change of
control of Nanogen, as defined in this letter. 
  
 In recognition of your efforts
and new role, Nanogen will pay you a one-time bonus of $150,000 upon approval by the Compensation Committee of the Board of Directors. This bonus shall be taxable to you and shall not be considered or offset to any degree by Nanogen in determining
relocation expense reimbursement or bonuses to be paid under Nanogen’s Executive Incentive Compensation Plan. 
  

 As part of this arrangement, you will be expected to relocate to the San Diego area. Reimbursement of your relocation
expenses shall be in accordance with the Nanogen Executive Relocation Policy. 
  
 Effect of Change in Control 
  
 Transaction Bonus. In the event of a transaction involving a Change in Control, in a transaction approved by the Company’s Board of Directors, which transaction results in the receipt by the Company’s stockholders of
consideration with a value representing, in the sole judgment of the Board of Directors, a significant premium over the average of the closing prices per share of the Company’s common stock as quoted on the Nasdaq National Market for 20 trading
days ending one day prior to the public announcement of such transaction (a “Change in Control Transaction”), you shall be paid a Transaction Bonus at the closing of such a transaction in the amount equal to two (2) times 50% of your Base
Salary in effect immediately preceding the closing of such a transaction. You shall also be paid said Transaction Bonus if the Company enters into a transaction approved by the Board of Directors which is not a Change in Control Transaction, but
which, nonetheless, involves a significant change in the ownership of the Company or the composition of the Board of Directors of the Company, and which results in significant additional value for the Company’s stockholders, as determined by
the Board of Directors in its sole discretion and as specifically designated a significant event by the Board of Directors. In the event you receive a Transaction Bonus, no bonus under the Executive Incentive Compensation Plan will be paid to you in
the year in which such Transaction Bonus is paid. 
  
 Vesting
of Stock Options. If the Company enters into a transaction which is a Change in Control Transaction, then all of your stock options received before the date of the transaction shall become exercisable in full and all of the shares of the common
stock of the Company awarded to you under the Company’s 1997 Stock Incentive Plan (or any subsequent plan) shall become fully vested. If the Company enters into a transaction which is not a Change in Control Transaction but which is a
Significant Event, then the Board of Directors may, in its sole discretion, determine that all, or a portion, of the Executive’s stock options received before the effective date of the transaction shall become exercisable in full and all, or a
portion, of the shares of the common stock of the Company awarded to Executive under the Company’s 1997 Stock Incentive Plan (or any subsequent plan) shall become fully vested. 
  
 Definition. “Change in Control” shall mean the occurrence of any of the following events: 
  

	 	•	The consummation of a merger or consolidation of the Company with or into another entity or any other corporate reorganization, if more than 50% of the combined voting power of the
continuing or surviving entity’s securities outstanding immediately after such merger, consolidation or other reorganization is owned by persons who were not stockholders of the Company immediately prior to such merger, consolidation or other
reorganization; 

  

	 	•	A change in the composition of the Board, as a result of which fewer than one-half of the incumbent directors are directors who either: 

  

	 	•	Had been directors of the Company 24 months prior to such change; or 

  

	 	•	Were elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the directors who had been directors of the Company 24 months prior to
such change and who were still in office at the time of the election or nomination; or 

  

	 	•	 Any “person” (as such term is used in sections 13(d) and 14(d) of the Exchange Act) by the acquisition or aggregation of securities is or becomes the
beneficial owner, directly or indirectly, of securities of the Company 

  

	 	 
representing 50% or more of the combined voting power of the Company’s then outstanding securities ordinarily (and apart from rights accruing under
special circumstances) having the right to vote at elections of directors (the “Base Capital Stock”); except that any change in the relative beneficial ownership of the Company’s securities by any person resulting solely from a
reduction in the aggregate number of outstanding shares of Base Capital Stock, and any decrease thereafter in such person’s ownership of securities, shall be disregarded until such person increases in any manner, directly or indirectly, such
person’s beneficial ownership of any securities of the Company. Thus, for example, any person who owns less than 50% of the Company’s outstanding shares, shall cause a Change in Control to occur as of any subsequent date if such person
then acquires an additional interest in the Company which, when added to the person’s previous holdings, causes the person to hold more than 50% of the Company’s outstanding shares. 

  
 The term “Change in Control” shall not include the Company’s
initial public offering or a transaction, the sole purpose of which is to change the state of the Company’s incorporation. 
  
 Employment with Nanogen is not for a specific term and can be terminated by you or by the Company at any time for any reason, with or without cause and with or without
notice. However, Nanogen agrees to prepare and execute a severance agreement with you in the event of termination of your employment for any reason other than Cause or if you terminate your employment with Nanogen for Good Reason. Under such
severance agreement, Nanogen or its successor shall pay you six (6) months of your base annual compensation and cover your health insurance benefit plan for 6 months. As used herein, “Cause” shall mean any act that violates this agreement
or the employment policies of Nanogen or any willful misconduct by you that may result in harm to Nanogen or its employees, directors or customers. The term “Good Reason” shall mean a material reduction, which is not corrected within
thirty (30) days by Nanogen after receipt of notice from you, in your duties, reduction in compensation except as part of, and at the same percentage as, an across the board reduction of the compensation of the senior management team, and relocation
of your office more than thirty (30) miles from your original place of employment with Nanogen. 
  
 The terms of this letter supercede and replace any other agreement between you and Nanogen. The terms of your employment cannot be changed except by an agreement in writing signed by you and an authorized
representative of Nanogen. 
  

	
	Sincerely yours,
	
	 /s/    HOWARD C. BIRNDORF

	 Howard C. Birndorf

  
 I accept the terms and conditions set
forth in this letter. 
  

	
	
	 /s/    DAVID G. LUDVIGSON

	 David G. LudvigsonCross License Agreement

 Exhibit 10.2 
  
 NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange
Commission (the “Commission”). Such portions have been redacted and are marked with a “[***]” in place of the redacted language. The redacted information has been filed separately with the Commission. 
  
 CROSS-LlCENSE_AGREEMENT on NT - proBNP 
  
 between 
  
 Syn-X Pharrna, Inc. 
 1 Marrnac Drive 
 Toronto, Ont. M9W lE7 
 Canada 
  
 -
hereinafter referred to as “Syn-X” - 
  
 and

  
 Roche Diagnostics GmbH 
 Sandhofer Strasse 116 
 D-68305 Mannheim

  
 - hereinafter referred to as “RDG” 
  

 This Cross License Agreement on proBNP (hereinafter referred to as “Agreement”) is entered into by and between
Roche Diagnostics GmbH, a German company having its principal place of business at Sandhofer Strasse 116, D-68305 Mannheim, Germany (hereinafter referred to as “RDG”), and Syn-X Pharma, Inc., having its principal place of business
at 1 Marmac Drive, Toronto, Ontario M9W lE7, Canada (hereinafter referred to as “Syn-X”). 
  
 RECITALS 
  

			
	WHEREAS,	  	RDG - the sole and exclusive licensor of certain RDG Licensed Patent Rights (as defined in Sect. 1.14 ) - controls worldwide intellectual property relating to the cardiovascular marker
proBNP (as defined in Sect. 1. 16); and
		
	WHEREAS,	  	Syn-X is in the diagnostics business and is desirous of developing, manufacturing and selling proBNP immunoassays on their Point of Care system; and
		
	WHEREAS,	  	Syn-X desires to obtain a non-exclusive license under RDG’s Licensed Patent Rights for proBNP to develop, manufacture, use and sell such proBNP immunoassays, and RDG is willing to
grant Syn-X such license; and
		
	WHEREAS,	  	Syn-X is the owner of certain Syn-X Licensed Patent Rights (as defined in Sect. 1.20) relating to the cardiovascular marker proBNP (as defined in Sect. 1. 16); and
		
	WHEREAS,	  	RDG desires to obtain a non-exclusive license under Syn-X’s Licensed Patent Rights for proBNP to develop, manufacture, use and sell proBNP immunoassays, and Syn-X is willing to
grant RDG such license; and
		
	WHEREAS,	  	 the Parties wish to cross-license their respective patent rights as provided in the
 Settlement Agreement (as defined in Sect. 1.18);

  
 NOW, THEREFORE, in
consideration of the recitals and the mutual covenants and obligations contained herein, RDG and Syn-X agree as follows: 
  
 ART. 1 DEFINITIONS 
  

	1.1	“Affiliate” shall mean: 

  

	 	a)	an organization, which directly or indirectly controls a Party to this Agreement; 

  

	 	b)	an organization, which is directly or indirectly controlled by a Party to this Agreement; 

  

	 	c)	an organization, which is controlled, directly or indirectly, by the ultimate parent company of a Party. 

  

 2/23 

 Control as per a) to c) is defined as owning fifty percent or more of the voting stock of a company or
having otherwise the power to govern the financial and the operating policies or to appoint the management of an organization. 
  
 With respect to RDG the term “Affiliate” shall not include Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990, U.S.A.
(“Genentech”) nor Chugai Pharmaceutical Co., Ltd, 1-9, Kyobashi 2-chome, Chuo-ku, Tokyo, 104-8301, Japan (“Chugai”), respectively, unless RDG opts for such inclusion of Genentech and/or Chugai by giving written notice to
Syn-X.
  

	1.2	“Combination Product” shall mean a Syn-X Licensed Product sold in combination with any other products and/or services, whether packaged together or separately, in
particular a Syn-X Licensed Product designed to also measure other parameters, whether packaged together or separately, if such Syn-X Licensed Product and such other products and/or services are offered for Sale at a one unit price.

  

	1.3	“Confidential Information” shall mean the terms and conditions of this Agreement and all written information and data provided by a Party to the other hereunder and
marked “Confidential” or a reasonable equivalent thereof or, if disclosed orally, visually or in some other form, is summarized in writing, is identified as “Confidential” and is provided to the other Party within thirty (30)
days of such disclosure, except any portion thereof which: 

  

	 	a)	is known to the recipient, as evidenced by its written records, before receipt thereof under this Agreement; 

  

	 	b)	is disclosed to the recipient without restriction after acceptance of this Agreement by a Third Party who has the right to make such disclosure; 

  

	 	c)	is or becomes part of the public domain through no breach of this Agreement; or 

  

	 	d)	is independently developed by or for the recipient, as evidenced by its written records, by individuals or entities without reference to the information disclosed hereunder.

  
 Notwithstanding the above, Syn-X herewith
agrees that RDG is entitled to provide to its exclusive licensor all the information necessary to be disclosed by RDG to its licensor to fulfill its contractual obligations agreed upon in the agreement under which RDG received the right to grant the
license under RDG Licensed Patent Rights, provided such licensor agrees to keep such information confidential pursuant to the terms of this Agreement. 
  

	1.4	“Contract Reporting Period” shall mean a period of three (3) consecutive months starting on the first day of the calendar year and each successive three (3)
consecutive month period, except that the first Contract Reporting Period shall begin on the Effective Date and shall end on December 31,2003. 

  

	1.5	 “Contract Year” shall mean a period of twelve (12) consecutive months during the term of this Agreement, which begins on January 1 each year,
except that the first 

  

 3/23 

	 	 
Contract Year shall begin on the Effective Date and shall end on December 31, 2003. 

  

	1.6	“Distributor” shall mean a distributor appointed by Syn-X or its Affiliates in the Territory or parts thereof for the marketing, Sales and/or promotion of Syn-X
Licensed Products. 

  

	1.7	“Effective Date” shall mean the last date on which a Party executes this Agreement. 

  

	1.8	“Improvements” shall mean substantial proBNP-related developments, discoveries and/or inventions made by Syn-X, whether or not patentable, and in particular
technical refinings, technological know-how, additions, ameliorations, amendments and/or modifications which improve or otherwise offer advantages in respect of the development and/or use and/or performance and/or manufacture of products for the
determination of proBNP but excluding those related to assay formats, detectable labels, instrumentation, packaging and the like. 

  

	1.9	“Licensed Patent Rights” shall mean RDG Licensed Patent Rights and/or Syn-X Licensed Patent Rights. 

  

	1.10	“Licensed proBNP Test” shall mean [***] 

  

	1.11	“Net Sales” shall mean [***]. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for Confidential Treatment. 

  
 4/23 

 “B” is the list selling price of the other products when sold separately, during the royalty
period being considered. 
  

	 	(ii)	If the Combination Product contains other products which are not sold or not offered for sale separately in a particular market or during the royalty period being considered, the
Net Sales of that Combination Product shall be determined as Sales of a Syn-X Licensed Product alone. 

  

	1.12	“Party” shall mean either Syn-X or RDG and “Parties” shall mean both Syn-X and RDG. 

  

	1.13	“RDG Licensed Field” shall mean [***] 

  

	1.14	“RDG Licensed Patent Rights” shall mean patents and patent applications listed in Exhibit A and which are either licensed by RDG or owned by RDG and all
substitutions, extensions, reexaminations, reissues, renewals, divisionals, continuations, or continuations-in-part therefore or thereof, and all foreign counterparts of the foregoing. Exhibit A shall be updated from time to time by RDG.

  

	1.15	“RDG Licensed Product” shall mean any product (including, without limitation, a diagnostic kit or packaged assay in its entirety, any component part of a diagnostic
kit or packaged assay, any human in-vitro diagnostic assay or research-use-only assay, any investigational-use-only assay, or any Analyte Specific Reagents (ASRs) or General Purpose Reagents (GPRs)) sold by RDG, the development, manufacture,
offering, distribution, use, import, export or sale of which, but for the license granted hereunder would infringe one (1) or more Valid Syn-X Claims in the country in which such product is developed, manufactured, offered, distributed, sold,
imported, exported or used. 

  
 Calibrators,
controls, standalone and universal reagents sold separately and even without the sublicense granted hereunder not infringing one (1) or more Valid Syn-X Claims in the country in which such calibrators, controls, standalone and universal reagents are
developed, manufactured, offered, distributed, sold, imported, exported or used are not RDG Licensed Products. 
  

	1.16	“proBNP” shall mean the N-terminal pro brain natriuretic peptide. 

  

	1.17	“Sale” or “sale” or “sold” shall mean to sell, hire, let, rent, lease or otherwise dispose of to a Third Party for monetary or
other valuable consideration, or consume in the performance of a service for a Third Party for monetary or other valuable consideration. 

  

	1.18	“Settlement Agreement” shall mean the Settlement Agreement between the Parties and Syn-X Pharma, U.S.A., LL.C. and Roche Diagnostics Corporation on even date
herewith. 

  

	1.19	“Syn-X Licensed Field” shall mean [***] 

  

	***	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for Confidential Treatment. 

  
 5/23 

	1.20	“Syn-X Licensed Patent Rights” shall mean patents and patent applications listed in Exhibit B and which are owned by Syn-X or Syn-X is the exclusive licensor, and
all substitutions, extensions, reexaminations, reissues, renewals, divisionals, continuations, or continuations-in-part therefore or thereof, and all foreign counterparts of the foregoing. Exhibit B shall be updated from time to time by Syn-X.

  

	1.21	“Syn-X Licensed Product” shall mean any product (including, without limitation, a diagnostic kit or packaged assay in its entirety, any component part of a
diagnostic kit or packaged assay, any human in-vitro diagnostic assay or research-use-only assay, any investigational-use-only assay, or any Analyte Specific Reagents (ASRs) or General Purpose Reagents (GPRs» sold by Syn-X, the development,
manufacture, offering, distribution, use, import, export or sale of which, but for the license granted hereunder would infringe one (1) or more Valid RDG Claims in the country in which such product is developed, manufactured, offered, distributed,
sold, imported, exported or used. 

  
 Calibrators,
controls, standalone and universal reagents sold separately and even without the sublicense granted hereunder not infringing one (1) or more Valid RDG Claims in the country in which such calibrators, controls, standalone and universal reagents are
developed, manufactured, offered, distributed, sold, imported, exported or used are not Syn-X Licensed Products. 
  

	1.22	“Territory” shall mean all countries worldwide. 

  

	1.23	“Third Party” shall mean a natural person, corporation, partnership, joint venture, trust, any governmental authority or other business entity or organization, and
any other recognized organization other than the Parties and/or their Affiliates. 

  

	1.24	“Valid RDG Claim” shall mean a claim of an issued and unexpired patent or patent application included in RDG Licensed Patent Rights, which claim has not been
withdrawn, cancelled or disclaimed, or held invalid or unenforceable by a final unappealable or unappealed order of a court or agency of competent jurisdiction, or which has not been admitted by the patentee to be invalid or unenforceable.

  

	1.25	“Valid Syn-X Claim” shall mean a claim of an issued and unexpired patent or patent application included in Syn-X Licensed Patent Rights, which claim has not been
withdrawn, cancelled or disclaimed, or held invalid or unenforceable by a final unappealable or un appealed order of a court or agency of competent jurisdiction, or which has not been admitted by the patentee to be invalid or unenforceable.

  

 6/23 

 ART. 2 GRANT OF RIGHTS BY RDG 
  

	2.1	Grant. RDG hereby grants to Syn-X, subject to the terms and conditions set forth herein, a non-exclusive license, under the RDG Licensed Patent Rights to use, have used,
develop, have developed, make, have made, possess, import, have imported, export, have exported, market, have marketed, offer for sale, have offered for sale, sell and have sold or otherwise distribute Syn-X Licensed Products under its own trademark
and/or trade name in the Syn-X Licensed Field throughout the Territory. 

  

	2.2	Syn-X shall not be entitled to grant sub-licenses to Third Parties but Syn-X shall be entitled to grant sublicenses to its Affiliates under the terms and conditions of this
Agreement. Such sublicense shall terminate automatically if sublicensed Affiliate no longer qualifies as an Affiliate. Syn-X shall be responsible for compliance of its sublicensed Affiliate with all obligations under this Agreement. In case of a
grant of such sublicense to its respective Affiliates or its termination Syn-X will inform RDG immediately. Sales to a distributor are not considered a sub-license event. 

  

	2.3	Syn-X and its Affiliates shall not set up any arrangement with a Third Party for supply or manufacture of components of Syn-X Licensed Products to such Third Party which by its
nature would grant such Third Party rights to sell Syn-X Licensed Products on its own behalf to Third Parties. 

  
 ART. 3 GRANT OF RIGHTS BY SYN-X 
  

	3.1	Grant. Syn-X hereby grants to RDG, subject to the terms and conditions set forth herein, a non-exclusive license, under the Syn-X Licensed Patent Rights to use, have used,
develop, have developed, make, have made, possess, import, have imported, export, have exported, market, have marketed, offer for sale, have offered for sale, sell and have sold or otherwise distribute RDG Licensed Products under its own trademark
and/or trade name in the RDG Licensed Field throughout the Territory. 

  

	3.2	RDG shall not be entitled to grant sub-licenses to Third Parties but RDG shall be entitled to grant sublicenses to its Affiliates under the terms and conditions of this Agreement.
Such sublicense shall terminate automatically if sublicensed Affiliate no longer qualifies as an Affiliate. RDG shall be responsible for compliance of its sublicensed Affiliate with all obligations under this Agreement. In case of a grant of such
sublicense to its respective Affiliates or its termination RDG will inform Syn-X immediately. 

  

	3.3	RDG and its Affiliates shall not set up any arrangement with a Third Party for supply or manufacture of components of RDG Licensed Products to such Third Party which by its nature
would grant such Third Party rights to sell RDG Licensed Products on its own behalf to Third Parties. 

  

 7/23 

 ART. 4 ROYALTIES AND PAYMENT TERMS 
  

	4.1	In consideration for the rights, covenant and license granted above under Art. 2 and for RDG’s agreement to the other terms and conditions hereof, Syn-X shall pay to RDG the
following: 

  

	4.1.1	[***] 

  

	4.1.2	[***] 

  

	4.1.3	[***] 

  

	4.1.4	[***] 

  

	4.2	[***] 

  

	4.3	Terms of Payment. [***] 

  

	4.4	[***] 

  

	4.5	 

  

	4.6	Reports. Syn-X is obliged to transmit to RDG within forty-five (45) days from the end of every Contract Reporting Period a written report showing [***] . The written
report or the nil returns shall be sent to the following address: 

  
 [***] 
  

	4.7	[***] 

  

	***	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for Confidential Treatment. 

  
 9/23 

 [***] 
  

	4.8	The obligations to pay shall only be fulfilled on the day on which the relevant amount of money is credited to the aforesaid account. 

  
 ART. 5 [***] 
  

	5.1	

  

	5.2	

  
 ART. 6 DEVELOPMENT, REGISTRATION AND MARKETING OF LICENSED PRODUCTS 
  

	6.1	Syn-X shall: 

  
 use all commercially reasonable efforts to develop and market Syn-X Licensed Products; 
  
 market only Syn-X Licensed Products which meet RDG’s worldwide Standard Performance Criteria and Specifications of such
Syn-X Licensed Product as defined in Exhibit C. 
  
 These
obligations of Syn-X represent a substantial part of this Agreement. 
  

	*** 	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for Confidential Treatment. 

  
 10/23 

	6.2	[***] 

  

	6.3	[***] Prior to the first commercial Sale of Syn-X Licensed Product, Syn-X shall prove in writing to RDG that its Syn-X Licensed Products meet RDG’s worldwide Standard
Performance Criteria and Specification as defined in Exhibit ’C. 

  
 ART. 7 IMPROVEMENTS 
  

	7.1	Throughout the term of this Agreement, Syn-X shall promptly inform RDG in writing of any Improvements, whether patentable or not. 

  

	7.2	[***] 

  

	7.3	[***] 

  

	7.4	[***] 

  

	***	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for Confidential Treatment. 

  

 11/23 

 ART. 8 BOOKS AND RECORDS 
  

	8.1	Procedures. Syn-X shall keep full and accurate accounting records of Net Sales of Syn-X Licensed Products in sufficient detail to determine the royalties payable to RDG. Such
records, together with all necessary supporting data, shall be kept at Syn-X’s offices at the address set forth above or such other address as Syn-X may indicate in writing to RDG. Upon reasonable notice to Syn-X, RDG shall have the right
during normal business hours to have an independent certified public accountant, selected by RDG and reasonably acceptable to Syn-X, audit on a confidential basis Syn-X’s records pertaining to Syn-X Licensed Product to verify the royalties
payable pursuant to this Agreement; provided, however, that such audit shall not (a) take place more frequently than once in a Contract Year, or (b) cover records for more than the preceding five (5) Contract Years. An adjustment in payment shall be
made upon demonstration of any underpayment or overpayment. 

  

	8.2	Cost of Audits. The fees and expenses of an audit requested by RDG pursuant to Sect. 8.1 shall be borne by RDG; provided, however, that if any audit reveals that Syn-X
underpaid the royalties due to RDG under this Agreement as to the period being audited by more than five percent (5 %) of the amount that was payable for such period, then Syn-X shall in addition to paying immediately to RDG any such deficiency,
reimburse RDG for the cost of such audit. 

  

	8.3	Retention Period. Syn-X shall retain all books and records required to be maintained hereunder for five (5) years from the date of the royalty payment to which they pertain.

  
 ART. 9 REPRESENTATIONS AND WARRANTIES 
  

	9.1	Intellectual Property Warranties by RDG. Each Party represents and warrants to the other Party as of the date of execution of this Agreement the following:

  

	 	a)	There are no suits, claims or proceedings pending or threatened against either Party or its licensor or any of its Affiliates that that Party is aware of in any court or by or
before any governmental body or agency with respect to the respective Licensed Patent Rights other than those which are subject to the Settlement Agreement between the Parties of even date herewith; 

  

	 	b)	Each Party controls all right, title and interest in and to the respective Licensed Patent Rights and each Party has the right to grant the non-exclusive license herein and to enter
into the obligations of this Agreement; 

  

	 	c)	Each Party’s control over the respective Licensed Patent Rights has not been obtained by it through any fraudulent activity or misrepresentation; and 

 

	 	d)	There are no Third Party obligations which would adversely affect each Party’s performance under this Agreement. 

  

 12/23 

	9.2	Consequential Damages. Neither Party shall be liable to the other Party for any indirect, special, or consequential damages for any cause of action a Party may have against
the other Party arising hereunder. 

  

	9.3	Patent Validity Actions. If either Party brings or prosecutes by itself, or either directly or indirectly assists any Third Party in any proceedings relating to the validity,
enforceability, inventorship, ownership, control or licensing of any of the respective Licensed Patent Rights, the other Party may, upon thirty (30) days written notice, terminate the license rights granted to the prosecuting Party hereunder in any
or all countries. For purposes of this Section “assist” shall not include any information that either Party is required or obligated to disclose or provide as a matter of law. 

  

	9.4	Either Party shall inform the other Party about revocation, invalidation, rejection, and abandonment of any respective License Patent Right and shall provide the other Party with an
amended Exhibit. 

  
 ART. 10 PATENT INFRINGEMENT 

 
 Each Party shall provide to the other all non-confidential and
non-privileged information in its possession concerning any infringement of Licensed Patent Rights by a Third Party within thirty (30) days of becoming aware of such infringement. If, during the term of this Agreement, either Party becomes aware
that any Third Party is infringing any Valid RDG or Syn-X Claims in a country where a Valid RDG or Syn-X Claim exists it shall notify the other Party to this Agreement. The respective patent owner or exclusive licensor shall have sole discretion in
the decision to institute legal proceedings against such Third Party and the other Party shall provide such assistance as the patent owner of exclusive licensor may reasonably request. 
  
 ART. 11 CONFIDENTIALITY AND PUBLIC ANNOUNCEMENTS 
  

	11.1	 Confidentiality. It is contemplated that in the course of the performance of this Agreement each Party may disclose from time to time Confidential
Information to the other Party. Each Party agrees (a) not to use Confidential Information received from the other for any purpose other than the performance of its obligations hereunder, and (b) not to disclose Confidential Information so received
to any Third Party, except as is required by a court or governmental authority. In the event that such disclosure to a Third Party becomes necessary or required, the disclosing Party shall give to the Party from whom the Confidential Information was
received the greatest practical prior written notice so as to permit the latter to take all possible action to perfect and/or safeguard its rights in the Confidential Information. The obligations of the Parties relating to Confidential Information
shall expire five (5) 

  

 13/23 

	 	 
years after termination of this Agreement. Any Third Party that receives Confidential Information in accordance with the terms of this Sect. 11.1 shall first
be required to consent in writing to the same restrictions as defined in this Sect. 11.1 before any disclosure of Confidential Information is made to such Third Party. 

  

	11.2	Public Announcements. Neither Party shall make any public announcement concerning the transactions contemplated herein or to make any public statement which includes the name
of the other Party or any of its Affiliates, or otherwise use the name of the other Party or any of its Affiliates in any public statement or document, except as may be required by law or judicial order (and then only following consultation with the
other Party), without the written consent of the other Party. 

  

	11.3	Notice to licensor. Not withstanding any other terms of this Agreement, RDG retains the right to notify its licensor of the RDG Licensed Patent Rights of RDG’s intent to
grant a license under RDG Licensed Patent Rights to Syn-X pursuant to this Agreement. RDG shall also be allowed to supply to said licensor all information necessary to satisfy its obligations, i.e. Syn-X’s Net Sales of Syn-X Licensed Products
and the royalties payable to RDG, subject to such licensor agreeing to keep such information confidential consistent with the terms of this Agreement. 

  
 ART. 12 TERM AND TERMINATION 
  

	12.1	Term. This Agreement shall commence on the Effective Date and each Party’s license shall remain in effect until the last to expire patent included in the respective
Licensed Patent Rights licensed to that Party, unless otherwise terminated earlier by operation of law or by acts of the Parties in accordance with the terms of this Agreement. 

  
 [***] 
  
 ART. 13 INDEMNIFICATION 
  

	13.1	 Indemnification by RDG. RDG shall indemnify, defend and hold harmless Syn-X and its officers, directors, employees, agents and representatives (hereinafter
referred to as “Syn-X Indemnitees”) from and against any and all liabilities, claims, demands, actions, suits, losses, damages, costs, and expenses (including reasonable attorneys’ fees) based on a Third Party claim which in turn is
based upon or arises out of RDG’s gross negligence, willful or deliberate misconduct, recklessness, or 

  

	*** 	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for Confidential Treatment. 

  
 15/23 

	 	 
breach of any covenant, agreement, representation or warranty made by RDG in this Agreement provided that RDG shall not be required to indemnify Syn-X or any
Syn-X Indemnitee to the extent it arises from the development, manufacture, offering, distribution, sale, import, export or use of Syn-X Licensed Products hereunder, Syn-X’s gross negligence, willful or deliberate misconduct, or recklessness,
Syn-X’s breach of this Agreement, or any other matter for which Syn-X is responsible to indemnify RDG pursuant to Sect. 11.2. 

  

	13.2	Indemnification by Syn-X. Syn-X shall indemnify, defend, and hold harmless RDG and its officers, directors, employees, agents and representatives (hereinafter referred to as
“RDG Indemnitees”) from and against any and all liabilities, claims, demands, actions, suits, losses, damages, costs, and expenses (including reasonable attorneys’ fees) based on a Third Party claim which in turn is based upon or
arising out of (i) the development, manufacture, offering, distribution, sale, import, export or use of Syn-X Licensed Products hereunder, and (ii) Syn-X’s gross negligence, willful or deliberate misconduct, reckless-ness, breach of any
covenant, agreement, representation, or warranty made by Syn-X in this Agreement; provided that Syn-X shall not be required to indemnify RDG or any RDG Indemnitee to the extent that it arises from RDG’s gross negligence, willful or deliberate
misconduct, or recklessness, RDG’s breach of this Agreement or any other matter for which RDG is responsible to indemnify Syn-X pursuant to Sect. 11.1. 

  

	13.3	Conditions of Indemnification. If either Party proposes to seek indemnification from the other under the provisions of this Article 12, it shall notify the other Party within
fifteen (15) business days of receipt of notice of any such claim or suit and shall cooperate fully with the other Party in the defense of such claims or suits. No settlement or compromise shall be binding on a Party hereto without its prior written
consent. 

  

	13.4	Termination of Indemnification Obligations. All obligations for indemnification on the part of a Party hereto shall expire two (2) years from the date of termination of this
Agreement, except with respect to claims already notified to the other Party prior to the end of such two (2) year period. 

  
 ART. 14 TRADE NAMES, TRADEMARKS AND LABELING 
  

	14.1	Either Party acknowledges that all trademarks, trade names, and trade dress of the other Party that shall accompany or shall be affixed to Syn-X or RDG Licensed Products during the
term of this Agreement are the property of the labeling Party. Neither Party shall claim or obtain any rights in any such trademarks, trade names, or trade dress of the other Party and shall take no action that shall in any way impair the other
Party’s right, title, and interest in and to such trademarks, trade names, and trade dress and shall not use for its own benefit or for the benefit of any Third Party any such trademarks, trade names, and trade dress during or after the term of
this Agreement unless such trademark, trade name or trade dress is being used in conflict with applicable laws and regulations. This shall not preclude either Party from using or claiming rights to a trademark, trade name or trade dress in existence
at the time of the Effective Date of this Agreement. 

  

 16/23 

	14.2	Labeling. the Parties shall consult regarding the appropriate labeling of patent numbers of the respective Licensed Patent Rights that should be noted on the packaging of the
licensed product within ninety (90) days of execution of this Agreement, or in the case of products not currently on the market, at least ninety (90) days prior to commercialization of such licensed product by the other Party. Syn-X shall print on
the packaging and the package insert of Syn-X Licensed Products the words “Manufactured under license from Roche Diagnostics GmbH”. 

  
 ART. 15 MISCELLANEOUS 
  

	15.1	Entire Agreement. This Agreement, together with the exhibits, constitutes the entire agreement between the Parties concerning the subject matter hereof and supersedes all
written or oral prior agreements or understandings with respect thereto. 

  

	15.2	Amendment or Modification. Any modification of or amendment to this Agreement must be made in writing. The same applies to any agreement waiving the written form.

  

	15.3	Severability. Should any provision of this Agreement be or become invalid, then the Parties hereto shall substitute for such invalid provision a new valid provision, which in
economic effect comes closest to the invalid provision that it can be reasonably assumed that the Parties would have concluded this Agreement including such new provision. In case such new provision cannot be found, the invalidity of any provision
of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid provision is of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have concluded this Agreement
without the invalid provisions. 

  

	15.4	Assignment. neither Party shall not assign this Agreement in whole or in part without the prior written consent of the other Party which consent shall not unreasonably be
withheld. Any permitted assignee shall assume all obligations of its assignor under this Agreement. No assignment shall relieve either Party of responsibility for the performance of any accrued obligation that it has hereunder.

  

	15.5	Independent Contractor. The relationship of RDG to Syn-X is that of independent contractor. In no event shall either Party hold itself out to others or allow itself to be
considered the agent, employee, or representative of the other Party. 

  

 17/23 

	15.6	Notices. All notices hereunder shall be in writing and shall be delivered personally, mailed by overnight delivery, registered or certified mail, postage prepaid, mailed by
express mail service or given by facsimile, to the following addresses of the respective Party: 

  

			
	 If to RDG:
	  	Roche Diagnostics GmbH
	 	  	Legal Department
	 	  	Sandhofer Strasse 116
	 	  	D-68305 Mannheim
	 	  	Germany
	 	  	Facsimile Number: [***]
		
	 With copy to:
	  	Roche Diagnostics GmbH
	 	  	Licensing Department
	 	  	Sandhofer Strasse 116
	 	  	D-68305 Mannheim
	 	  	Facsimile Number: [***]
		
	 If to Syn-X:
	  	Syn-X Pharma, Inc.
	 	  	1 Marmac Drive
	 	  	Toronto, Ont. M9W lE7
	 	  	Canada

  

	15.7 	Force Majeure. Any delay in the performance of any of the duties or obligations of either Party under this Agreement caused by an event outside the affected Party’s
reasonable control shall not be considered a breach of this Agreement, and the time required for performance shall be extended for a period equal to the period of such delay. Such events shall include, without limitation: acts of God; riots;
embargoes; labor disputes, including strikes, lockouts, job actions, or boycotts; fires; explosions; earthquakes; floods; shortages of material or energy; or other unforeseeable causes beyond the reasonable control and without the fault or gross
negligence of the Party so affected. The Party so affected shall give prompt notice to the other Party of such cause and shall take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as possible.

  

	15.8 	Binding Effect. This Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their respective assignees and successors in interest.

  

	15.9 	Waiver. No waiver or modification of any of the terms of this Agreement shall be valid unless in writing and signed by an authorized representative of the Parties. Failure by
either Party to enforce any rights under this Agreement shall not be construed as a waiver of such rights, nor shall a waiver by either Party in one or more instances be construed as constituting a continuing waiver or as a waiver in other
instances. 

  

	15.10 	Exhibits. All exhibits that are attached to this Agreement are incorporated herein by reference. 

  

	15.11 	Headings. The headings used in this Agreement are for convenience and reference purposes only and shall not affect the meaning or interpretation of this Agreement.

  

	15.12 	Counterparts. This Agreement may be executed in two (2) original counterparts, each of which shall be deemed an original, but both of which together shall constitute one and
the same instrument. 

  

 18/23 
  

	***	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for Confidential Treatment. 

	15.13 	Affiliate Compliance. Either Party guarantees that its Affiliates shall comply with the terms and conditions of this Agreement, and either Party remains liable directly to
the other Party for any breach thereof. 

  
 ART. 16 APPLICABLE
LAW - VENUE - ARBITRATION 
  

	16.1	Applicable Law. This Agreement shall be governed and construed in accordance with the laws of Germany without reference to its laws of conflict and without regard to the 1980
UN Convention on the International Sale of Goods. 

  

	16.2	Disputes and Arbitration. All disputes, controversies and differences which may arise between the Parties hereto in respect of this Agreement shall tried to be settled
amicably through mutual consultation within thirty (30) days of a written settlement request of either Party. 

  
 Any dispute or claim which may arise out of or in connection with this Agreement or the breach, termination or validity thereof shall be settled by final
and binding arbitration pursuant to the Rules of the German Institution of Arbitration (DIS e.V.; www.dis-arb.de ) as thereinafter provided: 
  

	 	a)	The arbitral tribunal shall consist of one (1) or three (3) arbitrators. If the Parties cannot agree on one arbitrator, each Party shall nominate in the request for arbitration and
the answer thereto one arbitrator and both arbitrators will then jointly appoint the third arbitrator as chairman of the arbitral tribunal. The chairman of the arbitral tribunal shall be a lawyer who has, at least, 15 years of experience with a law
firm or who was a judge of a court of general jurisdiction. If one Party fails to nominate its arbitrator or the Parties’ arbitrators cannot agree on the person to be named for the chairman within sixty (60) days, the German Institution of
Arbitration shall make the necessary appointments for arbitrator or chairman. 

  

	 	b)	The place of arbitration shall be in Frankfurt (Germany) and the arbitral proceedings shall be held in the English language. 

  

	 	c)	The award of the arbitral tribunal shall be final and judgement upon such an award may be entered in any competent court or application be made to any competent court for juridical
acceptance of such an award and order of enforcement. 

  
 IN WITNESS
WHEREOF, each Party has caused this Agreement to be executed on its behalf by its duly authorized officer as of the Effective Date. 
  

 19/23 

									
	 Roche Diagnostics GmbH /
	 	 	 	 Syn-X Pharma, Inc.

	 	 	 	 	 	 	 	 	 
					
	 	 	 /s/    H. J. NEUER
	 	 	 	 	 	 /s/    GEORGE JACKOWSKI

	By:	 	 H. J. Neuer
	 	 	 	By:	 	 George Jackowski 

	 Title:
	 	 Licensing Manager
	 	 	 	Title:	 	 Chairman & CEO

	 Date:
	 	 July 3, 2003
	 	 	 	Date:	 	 July 17, 2003

	 	 	 	 	 	 	 	 	 
	 	 	 /s/    CLAUDIA BOCKSTIEGEL
	 	 	 	 	 	 /s/    ROD WILSON

	By:	 	 Claudia Bockstiegel,
	 	 	 	By:	 	 Rod Wilson

	Title:	 	 Legal Counsel
	 	 	 	Title:	 	 President

	Date:	 	 July 3, 2003
	 	 	 	Date:	 	 

  

 20/24 

 EXHIBIT A 
 RDG Licensed Patent Rights 
  
 Medinnova patent rights exclusively licensed to RDG 
  

									
	 Country

	  	 Application No./
Publication No.

	  	 Application Date

	  	 Patent No.

	  	 Grant Date

	 Great Britain (priority application)
	  	9211686.2	  	03.06.1992	  	 	  	 
	 Australia
	  	43405/93	  	02.06.1993	  	667223	  	 
	 Canada
	  	2136961	  	02.06.1993	  	 	  	 
	 Japan
	  	6-500364	  	02.06.1993	  	 	  	 
	 EP designated countries:
	  	93913278.3	  	02.06.1993	  	0 648 228	  	04.11.1998
	 Austria
	  	 	  	 	  	 	  	 
	 Belgium
	  	 	  	 	  	 	  	 
	 Denmark
	  	 	  	 	  	 	  	 
	 France
	  	 	  	 	  	 	  	 
	 Germany
	  	 	  	 	  	 	  	 
	 Great-Britain
	  	 	  	 	  	 	  	 
	 Ireland
	  	 	  	 	  	 	  	 
	 Italy
	  	 	  	 	  	 	  	 
	 Luxembourg
	  	 	  	 	  	 	  	 
	 Netherlands
	  	 	  	 	  	 	  	 
	 Spain
	  	 	  	 	  	 	  	 
	 Sweden
	  	 	  	 	  	 	  	 
	 Switzerland
	  	 	  	 	  	 	  	 
	 USA
	  	08/338558	  	02.06.1993	  	5,786,163	  	28.07.1998

  

 21/23 

 EXHIBIT A - continued 
  
 RDG patent rights 
  

									
	 Country

	  	 Application No./
Publication No.

	  	 Application Date

	  	 Patent No.

	  	 Grant Date

	 Case 18931
	  	 	  	 	  	 	  	 
	 High sensitive
	  	 	  	 	  	 	  	 
	 NTproBNP assay
	  	 	  	 	  	 	  	 
	 Gennany (priority application)
	  	19903489.3	  	29.01.1999	  	 	  	 
	 Australia
	  	25451/00	  	27.01.2000	  	 	  	 
	 Canada
	  	2359667	  	27.01.2000	  	 	  	 
	 China
	  	00803234.3/1339107	  	27.01.2000	  	 	  	 
	 EP
	  	00903642.7/1 151 304	  	27.01.2000	  	 	  	 
	 Hungary
	  	P0105195	  	27.01.2000	  	 	  	 
	 Israel
	  	144062	  	27.01.2000	  	 	  	 
	 Japan
	  	2000-596377	  	27.01.2000	  	 	  	 
	 Mexico
	  	007637	  	27.01.2000	  	 	  	 
	 New Zealand
	  	512762	  	27.01.2000	  	 	  	 
	 Norway
	  	20013698	  	27.01.2000	  	 	  	 
	 Poland
	  	 	  	27.01.2000	  	 	  	 
	 Russia
	  	2001123936	  	27.01.2000	  	 	  	 
	 South Africa
	  	2001/6193	  	27.01.2000	  	2001/6193	  	31.07.2002
	 South-Korea
	  	01-7009587	  	28.01.2000	  	 	  	 
	 U.S.A.
	  	09/890442	  	27.01.2000	  	 	  	 
	 Case 21299
 Cardiac risc
 assessment using
 CRP, proBNP
 and TnT/I
	  	 	  	 	  	 	  	 
	 US (priority application)
	  	60/380413	  	14.05.2003	  	 	  	 

  

 22/23 

 EXHIBIT B 
 Syn-X Licensed Patent Rights 
  
 [***] 
  

	***	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for Confidential Treatment. 

 Exhibit C 
  
 Performance Criteria and Specifications of SynX Licensed Products 
  

[***] 
  

	***	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for confidential treatment.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]